18 results about "Immunologic assay" patented technology

The invention provides a kit for quantitatively detecting VEGF (Vascular Endothelial Growth Factor) by using a chemiluminescence method as well as a preparation method and a detection method of the kit. The kit comprises a VEGF reagent 1 which is a diluent 1; the VEGF reagent 2 comprises a peroxidase-labeled VEGF antibody and a diluent 2; the VEGF coated plate comprises a VEGF coated antibody, a diluent 1, a diluent 3, a diluent 4 and a chemiluminescent plate; the diluent 1 is a phosphate buffer solution; the diluent 2 is a Tris buffer solution containing fetal calf serum and an HRP enzyme stabilizer; the diluent 3 is a carbonate buffer solution; and the diluent 4 is a phosphate buffer solution containing sodium caseinate and a light-emitting plate stabilizer. According to the detection kit, the double antibody sandwich method immunoassay principle is combined with enzyme labeling and catalytic chemiluminescence immunoassay, the content of the VEGF is quantitatively determined, the detection kit can be prepared with low cost, accurate determination of the VEGF can be achieved, and the detection kit has high sensitivity and good stability.

The presently described and claimed technology relates immunoassay methods of assessing a subject's Alzheimer's Disease status and zygosity for the APOE ε4 allele.

Provided is a heterohybridoma-based method of generating recombinant rabbit monoclonal antibodies, recombinant anti-IL-6 receptor-alpha (IL-6Rα) antibodies generated using such methods, and immune assay methods kits employing such antibodies.

This invention provides novel and improved DHEAS assay reagents and assays, as well as methods for manufacturing and using them to detect DHEAS levels in biological samples. [Solution] An immunoassay reagent containing a dehydroepiandrosterone sulfate-fluorescein (DHEAS-FITC) conjugate or a dehydroepiandrosterone sulfate-carboxymethoxylaminodimethylacridinium ester (DHEAS-CMO-DMAE) conjugate is disclosed. Immunosay kits and devices containing one or more DHEAS conjugates are also disclosed. Methods for producing and using DHEAS conjugates are further disclosed.

Described herein are devices and methods for improved detection and quantitation of biomolecules. Devices and methods may include a microfluidic biosensing platform for measuring electrical impedance changes in the presence of target analytes from sinusoidal input voltages to improve the sensitivity of immunoassays. In one embodiment, the described devices and methods may provide a point-of-care immunoassay platform for quantitative diagnostics using signal-enhancing microparticles to improve sensitivity and the limit-of-detection.

The present invention addresses the problem of providing a transparent conductive film that can be used in a rapid and simple inspection device, and a biochip therefor. In particular, provided are a transparent conductive film for immunoassay using electrochemiluminescence and a biochip thereof. Provided is a laminate comprising a transparent conductive film and a porous film laminated on the transparent conductive film, in which the porous film has permeability to an electrolyte solution.

The present disclosure is directed to methods for fabricating cellulose-based microneedles with exceptional wicking properties which can be used for rapid extraction of dermal interstitial fluid (ISF). Microneedle arrays are fabricated through a combination of compression molding and laser etching, utilizing microcrystalline cellulose, a biocompatible material with excellent wicking properties. These microneedles are mechanically robust and can autonomously extract fluid from the skin without the need for external instruments. As such, they can be directly integrated with paper-based lateral flow immunoassays for point-of-care disease detection.

The invention relates to an immunoassay reagent for dengue fever NS1 antigen detection and a preparation method thereof. According to the self-driven micro-fluidic chip, an up-conversion luminescent nano material (UCP) is adopted to mark a dengue fever NS1 antigen specific antibody. The invention further relates to a testing and using method of the up-conversion luminescence method self-driven micro-fluidic chip, the method is used for quantitatively determining the content of the dengue NS1 antigen, the method has the advantages of being short in detection period, high in sensitivity and low in background interference, and support is provided for prevention, diagnosis and treatment of dengue.

Predicting treatment benefits of immune checkpoint inhibitor drugs (ICIs) without resorting to advanced genomic or immunologic assays is a major unmet clinical need. This disclosure provides a predictive model using machine-learning approaches based on routine laboratory test results in clinical practice.

Provided herein are compositions and methods related to improved assays for determining the condition of neurodegenerative disease and providing treatment. Also provided herein are compositions and methods comprising improved antibodies for assays, including immunoassays for diagnosing Alzheimer's disease and providing treatment.

This invention provides an immunological assay method capable of suppressing nonspecific reactions caused by immunoglobulin M, abbreviated as IgM, contained in a sample for measurement, and reagents used in this immunological assay method. [Solution] The present invention provides an immunological assay method for measuring a target substance in a sample, comprising performing an antigen-antibody reaction at least once in the presence of an enzyme that specifically degrades IgM, and an immunological assay reagent used in the immunological assay method, comprising an enzyme that specifically degrades IgM.

A labeled antibody according to the present invention is obtained by using a linker to bind a full-length antibody and a labeling substance. The linker is formed by binding a first reactive group of a crosslinking agent to the full-length antibody and binding a second reactive group of the crosslinking agent to the labeling substance. The molecular weight of the labeling substance is 10,000 or greater, and the molecular weight of the crosslinking agent is 270 to 1350.

Provided are compounds, compositions, kits, systems, devices, and methods for improving an assay such as, for example, a multiplexed PCR assay (e.g., a multiplexed immuno-PCR assay). A solid support (e.g., a bead) may be provided according to some embodiments of the present invention. The solid support may comprise an encoding agent (e.g., a dye), a nucleic acid sequence (e.g., an oligonucleotide and / or primer); and a molecular recognition element (e.g., an antibody). A detection reagent may be provided according to some embodiments of the present invention. The detection reagent may comprise a molecular recognition element (e.g., an antibody) and a nucleic acid tag. In some embodiments, at least a portion of the nucleic acid sequence of the solid support and at least a portion of the nucleic acid target tag of the detection reagent are configured to participate in a nucleic acid amplification process. A solid support and detection reagent may bind to the same target, thereby forming a reagent pair.

Described herein are apparatuses and methods for the processing and / or measurements of chemical or biochemical samples on a digital microfluidic device. Also described are methods to configure and operate the modules for efficient processing and measurements of the samples on the device. The apparatus can be used in applications such as DNA / RNA / protein / cell concentration / purification, real-time PCR, isothermal amplification, immunoassay, cell-based assay, library preparation for NGS sequencing, etc.

Analysis of cell populations for both research and clinical applications such as cell therapy is often performed on whole blood that is close to 24 hours old. The reason for this is that the analysis site is removed from the blood draw site so that blood must be shipped overnight to the analysis site. During the 24-hour shipping period granulocytes, primarily neutrophils, breakdown into cell debris including release of nucleic acids into the blood. Such debris is known to interfere with immunological assays and with rethawing following freezing of samples. There is a need for a method and apparatus to solve this issue. The invention disclosed herein solves the issue. Following blood draw at the draw site the neutrophils are removed using an apparatus that draws blood into a tube that contains anti-CD15 bound to nickel magnetic particles. Following mixing the tube is placed in a magnetic field and then while still in the magnetic field the blood with neutrophils removed is transferred into a new tube for shipment to the analysis site.

A device, system and method for collecting and eluting aerosol particles contained in a breath sample of a human or animal for the purpose of sampling non-volatile respiratory pathogens present in the breath sample. In at least some embodiments, the present invention provides such a device, system and method to collect, preserve, concentrate and release pathogen-specific biomarkers from breath aerosols for the subsequent analysis with immunoassays and molecular assays for the clinical diagnosis of respiratory tract infections in humans. The sampling device comprises an aqueous solution dissolvable polymer membrane installed in a housing of the sampling device in the flow path of the breath aerosol that sorbs the aerosol particles. The sampling device further comprises an engagement means for releasably engaging an elution device to the housing for introducing an aqueous solution into the housing and for dissolving the polymer membrane upon contact with the aqueous solution.

This testing tool includes at least a flow channel through which a sample containing red blood cells and a substance to be measured is circulated. The flow channel includes at least a sample supply part to which the sample is supplied, a blood cell separation membrane for separating the red blood cells from the sample, and a detection part for detecting the substance to be measured in the sample. The detection part is located downstream of the blood cell separation membrane in a flow direction of the sample, and at least one polymer of a poly(meth)acrylic acid having a weight average molecular weight of 35,000 to 1,000,000 inclusive and a poly(meth)acrylic acid inorganic salt having a weight average molecular weight of 35,000 to 1,000,000 inclusive is contained in at least a part of the region lying between the sample supply part and the blood cell separation membrane in the flow direction of the sample in the flow channel.